Global Leading Market Research Publisher QYResearch announces the release of its latest report “Oral Diabetes Medicine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oral Diabetes Medicine market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Oral Diabetes Medicine was estimated to be worth US68,500millionin2025andisprojectedtoreachUS68,500millionin2025andisprojectedtoreachUS89,000 million by 2032, growing at a CAGR of 3.8% from 2026 to 2032. For endocrinologists, primary care physicians, and pharmaceutical portfolio managers, the core business imperative lies in prescribing and developing oral diabetes medicines that address the critical need for effective, safe, and convenient glycemic control in type 2 diabetes (T2DM) patients, with emerging classes providing cardiorenal protective benefits beyond glucose lowering. Oral diabetes medicines (antidiabetic agents) are categorized by mechanism of action: DPP-4 inhibitors (sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), vildagliptin (Galvus)) – enhance incretin (GLP-1, GIP) half-life, glucose-dependent insulin secretion, suppress glucagon, neutral weight, low hypoglycemia risk; GLP-1 receptor agonists (oral semaglutide (Rybelsus), TTP273 (vTv Therapeutics) – first oral peptide, stimulates insulin secretion, suppresses glucagon, slows gastric emptying, promotes satiety (weight loss), cardiovascular benefit; SGLT-2 inhibitors (canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), ertugliflozin (Steglatro)) – block glucose reabsorption in renal proximal tubule, promote glycosuria (glucose excretion), weight loss, blood pressure reduction, cardiorenal protection (heart failure, chronic kidney disease (CKD)). Other classes: metformin (biguanide) – first-line, reduces hepatic glucose output, improves insulin sensitivity; sulfonylureas (glimepiride, glipizide, glyburide) – stimulate insulin secretion, hypoglycemia risk, weight gain; thiazolidinediones (TZDs) (pioglitazone, rosiglitazone) – PPAR-γ agonist (peroxisome proliferator-activated receptor gamma), improves insulin sensitivity, edema, weight gain, cardiovascular concerns; alpha-glucosidase inhibitors (acarbose, miglitol, voglibose) – delay carbohydrate absorption, flatulence; meglitinides (repaglinide, nateglinide) – rapid-acting insulin secretagogue, taken before meals. Applications: type 1 diabetes (limited oral options, typically insulin-requiring) + metformin off-label; type 2 diabetes (90-95% of diabetics) primary target. Key players: Sanofi, Biocon (India), Boehringer Ingelheim (Germany), Merck & Co. (US), Johnson & Johnson (US), Novartis (Switzerland), Novo Nordisk (Denmark), Takeda (Japan), AstraZeneca (UK/Sweden), Huadong Medicine (China), Eli Lilly and Company (US), Deyuan Pharmaceutical (China), Hengrui Medicine (China). The market is driven by global diabetes epidemic (540M adults (2025), projected 640M (2030)), aging population, obesity prevalence, and guideline updates (ADA/EASD (American Diabetes Association/European Association for the Study of Diabetes) recommending SGLT-2 inhibitors and GLP-1 receptor agonists for cardiorenal protection (independent of baseline A1c (Hemoglobin A1c)).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5975763/oral-diabetes-medicine
The Oral Diabetes Medicine market is segmented as below:
Sanofi
Biocon
Boehringer Ingelheim
Merck & Co.
Johnson & Johnson
Novartis
Novo Nordisk
Takeda
AstraZeneca
Huadong Medicine
Eli Lilly and Company
Deyuan Pharmaceutical
Hengrui Medicine
Segment by Type
DPP-4
GLP-1
SGLT-2
Segment by Application
Type 1 Diabetes
Type 2 Diabetes
1. Market Drivers: Diabetes Epidemic, Novel Classes (SGLT-2, GLP-1), and Guidelines
Several powerful forces are driving the oral diabetes medicine market:
Global diabetes epidemic (540M adults) – IDF (International Diabetes Federation) projections (640M by 2030). China, India, US highest. Aging population, obesity, sedentary lifestyle.
Cardiorenal protective benefits (SGLT-2, GLP-1) mandate – EMPA-REG OUTCOME (empagliflozin), DECLARE-TIMI (dapagliflozin), LEADER (liraglutide) trials show reduction in major adverse cardiovascular events (MACE (major adverse cardiovascular events)), hospitalization for heart failure (HF), progression of chronic kidney disease (CKD). ADA/EASD guidelines recommend SGLT-2 inhibitors or GLP-1 receptor agonists for patients with established cardiovascular disease (CVD) or CKD/high risk.
Oral GLP-1 receptor agonist (semaglutide) (Rybelsus) approved 2019 – First oral peptide (co-formulated with SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) absorption enhancer). Competes with injectable GLP-1 agonists (once-weekly semaglutide (Ozempic), dulaglutide (Trulicity), liraglutide (Victoza)). Convenience, weight loss.
Recent market data (December 2025): According to Global Info Research analysis, DPP-4 inhibitors largest revenue share (~35%) — sitagliptin (Merck) generic erosion, linagliptin (Boehringer), saxagliptin (AstraZeneca). SGLT-2 inhibitors second (~30%) — empagliflozin (Boehringer/Lilly), dapagliflozin (AstraZeneca), canagliflozin (J&J), plus generics. GLP-1 receptor agonists (oral semaglutide (Novo Nordisk)) fastest-growing segment (~25%) 12-15% CAGR. Others (metformin, sulfonylureas, TZDs, alpha-glucosidase inhibitors, meglitinides) ~10%. Type 2 diabetes dominant (95%+). North America (US) largest market (40%). Europe (25%). Asia-Pacific (China, India) 30% (fastest-growing, 5-6% CAGR). Novo Nordisk (Rybelsus, Ozempic), Merck (Januvia), Boehringer/Lilly (Jardiance, Tradjenta), AstraZeneca (Farxiga, Onglyza) leaders. Biocon, Huadong, Deyuan, Hengrui (China, India) generic manufacturers.
2. Drug Classes and Key Players
| Class | Mechanism | Examples (Brand) | A1c Reduction | Weight Effect | Hypoglycemia Risk | CV Benefits | Renal Benefits | Share |
|---|---|---|---|---|---|---|---|---|
| DPP-4 | Incretin enhancement | Sitagliptin (Januvia), linagliptin (Tradjenta) | 0.5-0.8% | Neutral | Low | Neutral | Neutral | ~35% |
| SGLT-2 | Glycosuria, natriuresis | Empagliflozin (Jardiance), dapagliflozin (Farxiga) | 0.7-1.0% | Loss (2-3kg) | Low | Reduce MACE, HF | Reduce CKD progression | ~30% |
| GLP-1 RA (oral) | Insulin secretion, satiety | Semaglutide (Rybelsus) | 1.0-1.5% | Loss (4-6kg) | Low (except sulfonylurea/insulin) | Reduce MACE, stroke | Reduce albuminuria | ~25% |
Key clinical trials: DPP-4 (SAVOR-TIMI 53, EXAMINE, TECOS) no CV benefit (non-inferior). SGLT-2 (EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI, VERTIS CV). GLP-1 (LEADER, SUSTAIN-6, REWIND). Metformin first-line (UKPDS (United Kingdom Prospective Diabetes Study)). Sulfonylureas second/third-line (hypoglycemia risk, weight gain). TZDs (pioglitazone) CV benefit (PROactive) but fluid retention, fracture risk, bladder cancer (uncertain). Alpha-glucosidase inhibitors (acarbose) modest efficacy.
Exclusive observation (Global Info Research analysis): Oral diabetes medicine market is shifting from DPP-4 inhibitors (mature, generic erosion) to SGLT-2 inhibitors (cardiorenal protection) and oral GLP-1 receptor agonists (weight loss, convenience). Metformin remains first-line (low cost, safety, CV benefit). Sulfonylureas declining (hypoglycemia, weight gain). SGLT-2 class (Jardiance, Farxiga) now preferred for T2DM with HF or CKD regardless of A1c. Oral semaglutide (Rybelsus) expanding GLP-1 market beyond injectable. China domestic manufacturers (Huadong Medicine (TTP273 oral GLP-1), Deyuan Pharmaceutical (canagliflozin generic), Hengrui Medicine (SGLT-2 inhibitor)) capture local market.
User case – type 2 diabetes with CKD (December 2025): US patient (65 yo, T2DM, eGFR 45 mL/min, albuminuria) prescribed empagliflozin (Jardiance) 25mg daily (SGLT-2 inhibitor). Reduces risk of CKD progression, HF hospitalization, CV events. Also taking metformin 1000mg BID. HbA1c (Hemoglobin A1c) 7.2%.
User case – obesity and T2DM (January 2026): Indian patient (50 yo, BMI 32, HbA1c 8.5%) started on oral semaglutide (Rybelsus) 14mg daily (weight loss, glycemic control). Also lifestyle modification. HbA1c reduced to 6.8% after 6 months, weight loss 6kg.
3. Key Challenges and Technical Difficulties
Side effects (gastrointestinal for GLP-1, genital infections for SGLT-2, hypoglycemia for sulfonylureas/insulin) – Nausea, vomiting, diarrhea (GLP-1; dose titration). Genitourinary infections (SGLT-2; increased glucose in urine). Hypoglycemia risk (sulfonylureas, meglitinides, insulin) mitigated by patient education, CGM (continuous glucose monitoring).
Cost and formulary access (SGLT-2, GLP-1 are expensive) – Branded SGLT-2 inhibitors and GLP-1 agonists cost US400−800/monthwithoutinsurance.Generics(metformin,sulfonylureas,pioglitazone)400−800/monthwithoutinsurance.Generics(metformin,sulfonylureas,pioglitazone)10-50/month. Prior authorization, step therapy.
Technical difficulty – patient adherence to once-daily dosing: Oral semaglutide (Rybelsus) requires first thing in morning (at least 30 minutes before food, drink, other medications) with ≤120mL water. Complex instructions reduce adherence.
Technical development (October 2025): Novo Nordisk (Denmark) announced once-daily oral GLP-1/GIP dual agonist (amycretin) phase 2 trial for T2DM and obesity (superior weight loss). Potential oral semaglutide successor.
4. Competitive Landscape
Key players include: Sanofi (France – glimepiride, insulin), Biocon (India – biosimilars, generic metformin), Boehringer Ingelheim (Germany – empagliflozin (Jardiance), linagliptin (Tradjenta), metformin), Merck & Co. (US – sitagliptin (Januvia)), Johnson & Johnson (US – canagliflozin (Invokana)), Novartis (Switzerland – vildagliptin (Galvus)), Novo Nordisk (Denmark – oral semaglutide (Rybelsus), liraglutide), Takeda (Japan – alogliptin (Nesina), pioglitazone), AstraZeneca (UK/Sweden – dapagliflozin (Farxiga), saxagliptin (Onglyza)), Huadong Medicine (China – TTP273 oral GLP-1), Eli Lilly (US – dulaglutide (Trulicity) injectable, tirzepatide (Mounjaro) injectable), Deyuan Pharmaceutical (China), Hengrui Medicine (China). Novo Nordisk, Boehringer/Lilly, AstraZeneca, Merck leaders.
Regional dynamics: North America (Novo Nordisk, Merck, Boehringer, Lilly, AstraZeneca, J&J). Europe (Novo Nordisk, Boehringer, AstraZeneca, Sanofi, Novartis). Asia-Pacific (Biocon (India), Huadong, Deyuan, Hengrui (China)).
5. Outlook
Oral diabetes medicine market will grow at 3.8% CAGR to US$89 billion by 2032, driven by type 2 diabetes prevalence, SGLT-2 and GLP-1 adoption, and oral semaglutide. Technology trends: oral GLP-1/GIP dual agonists (amycretin, orforglipron), once-weekly oral DPP-4 (omarigliptin withdrawn), and fixed-dose combinations (SGLT-2 + metformin, SGLT-2 + DPP-4). Asia-Pacific growth fastest (5-6% CAGR). Generics erode DPP-4, metformin, sulfonylureas prices.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
